Dooseop Kim

This inventor holds 31 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Kainos Medicine Inc.. Active years: 1992-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dooseop Kim. Retrieved from https://idiyas.com/inventor/dooseop-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 3)

% Patents Active = 90.3

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 5.4

ph-index = 12

Forward Citations = 548(Granted Patents)

Location History:

Scotch Plains, NJ (US) (1992 - 1995)
Westfield, NJ (US) (1997 - 2013)
Seoul, KP (2017)
Seoul, KR (2015 - 2018)

Company Filing History:

Merck Sharp + Dohme Corp.

Years Active: 1992-2018

Loading Chart...

Areas of Expertise:

Potassium Channel Inhibitors

Dipeptidyl Peptidase Inhibitors

Chemokine Receptor Modulators

Diabetes Treatment

CETP Inhibitors

Antihyperlipidemic Agents

Angiotensin II Antagonists

Benzoxazole Derivatives

Heterocyclic Compounds

Tricyclic Compounds

Pyrrolidine Modulators

Acidic Functional Groups

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10000484 - Inhibitors of the renal outer medullary potassim channel (2018-06-19),

2. 9777002 - Inhibitors of the renal outer medullary potassium channel (2017-10-03),

3. 9527830 - Inhibitors of the renal outer medullary potassium channel (2016-12-27),

4. 9271969 - Compounds as inhibitors of diacylglycerol O-acyltransferase type 1 enzyme (2016-03-01),

5. 9062070 - Inhibitors of the renal outer medullary potassium channel (2015-06-23),

6. 9056859 - Inhibitors of the renal outer medullary potassium channel (2015-06-16),

7. 8445480 - CETP inhibitors derived from benzoxazole arylamides (2013-05-21),

8. 8440668 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes (2013-05-14),

9. 8399507 - Antidiabetic tricyclic compounds (2013-03-19),

10. 8334290 - CETP inhibitors (2012-12-18),

11. 8168637 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes (2012-05-01),

12. 7390809 - Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes (2008-06-24),

13. 7307164 - β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes (2007-12-11),

14. 7125887 - Pyrrolidine modulators of CCR5 chemokine receptor activity (2006-10-24),

15. 7125873 - Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes (2006-10-24),

Title: The Innovative Journey of Inventor Dooseop Kim

Introduction:

Dooseop Kim, a prolific inventor based in Westfield, NJ, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 31 patents under his name, his work has revolutionized the treatment of various medical conditions.

Latest Patents:

Kim’s latest patents focus on "Inhibitors of the Renal Outer Medullary Potassium Channel" – compounds that act as inhibitors of the ROMK (Kir1.1) channel. These compounds have shown promise as diuretic and natriuretic agents, aiding in the treatment of cardiovascular diseases such as hypertension, heart failure, and chronic kidney disease. They also play a crucial role in conditions associated with excessive salt and water retention.

Career Highlights:

Having worked with renowned companies like Merck & Company, Inc. and Merck Sharp & Dohme Corporation, Kim has honed his skills and expertise in the pharmaceutical industry. His innovative approach to drug discovery and development has led to the successful filing of numerous patents that have the potential to impact millions of lives globally.

Collaborations:

Throughout his career, Kim has collaborated with esteemed colleagues such as Malcolm Maccoss and Sander G Mills. These partnerships have not only enhanced the quality of his work but have also facilitated the exchange of knowledge and ideas within the pharmaceutical research community.

Conclusion:

Inventor Dooseop Kim’s dedication to innovation and his relentless pursuit of scientific advancements have cemented his legacy in the field of pharmaceuticals. His patented inventions stand as a testament to his ingenuity and commitment to improving healthcare outcomes for individuals around the world.

Profile summary based on public USPTO records.